(Q37650203)

21 August 2017

1 reference

title

Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (English)

1 reference

21 August 2017

1 reference

Wendy Stock

1

1 reference

21 August 2017

publication date

1 February 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

51

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

188-198

1 reference

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Bone marrow transplant in Ph+ ALL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Recent approaches in acute lymphoblastic leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Src kinases as targets for B cell acute lymphoblastic leukaemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903452834

10.3109/10428190903452834

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference